Patents Assigned to JBS Science Inc.
-
Publication number: 20230183672Abstract: Provided herein includes a method for characterizing a target cell-free nucleic acid (cfNA) molecule present in a biological sample such as a urine sample. It comprises isolating total cfNAs from the biological sample without prior preprocessing such as centrifugation to remove cell debris, and characterizing the target cfNA molecule based on the isolated total cfNAs. When the target cfNA is a low molecular weight (LMW) molecule, the method additionally comprises a fractionation step to obtain LMW nucleic acids from the total cfNAs before characterization. The method can detect significantly more copies of the target cfNA molecule compared with existing methods which typically discard the cell debris from the biological sample. Another method is also provided, which substantially recovers cfNAs from the usually discarded cell debris, thus also capable of detecting significantly more copies of the target cfNA molecule.Type: ApplicationFiled: July 19, 2022Publication date: June 15, 2023Applicant: JBS Science Inc.Inventors: Zhili WANG, Wei SONG, Selena LIN
-
Publication number: 20210017611Abstract: A method and a kit for identifying HBV-host junction sequences (HBV-JSs) from a biological sample are provided. The method includes: preparing a DNA sample (e.g. DNA library) and performing at least one round of enrichment. Each round of enrichment includes a sub-step of capturing HBV DNA sequence-containing DNA molecules from the DNA sample by means of an HBV probe set, which includes a plurality of elaborately designed HBV primers configured to selectively and respectively target different regions of an HBV genome, and each HBV primer is labelled with an immobilization portion such as biotin moiety so as to allow immobilization onto a solid support such as magnetic beads. The method and kit can be used for non-invasively detecting HBV-JSs using a urine sample and other body fluids. The information of the HBV-JSs can be further utilized in the screening, diagnosis, prognosis and management of HBV-associated HCC.Type: ApplicationFiled: July 17, 2020Publication date: January 21, 2021Applicant: JBS Science Inc.Inventors: Selena LIN, Wei SONG
-
Publication number: 20200263259Abstract: Provided herein are a kit and method for detecting mutations in CTNNB1, and their use in detection and management of hepatocellular carcinoma (HCC). The kit comprises a first pair of primers, configured to specifically bind sequences flanking the genomic region for amplifying the genomic region in a first PCR reaction; and at least one clamp, each configured to bind to one first allele but not any second allele at an annealing temperature in the first PCR reaction to thereby selectively suppress amplification of the one first allele but still allow amplification of other second allele(s). A method for detecting or monitoring recurrence of HCC is further disclosed, which comprises determining levels of five DNA markers, including CTNNB1 mutations, hTERT mutations, TP53 mutations, RASSF1A methylation, and GSTP1 methylation.Type: ApplicationFiled: March 23, 2020Publication date: August 20, 2020Applicant: JBS Science Inc.Inventors: Wei Song, Surbhi Jain, Jamin Dean Steffen
-
Patent number: 10689709Abstract: Provided herein are a kit and method for detecting mutations in CTNNB1 and hTERT, and their use in detection and management of hepatocellular carcinoma (HCC). The kit comprises a first pair of primers, configured to specifically bind sequences flanking the genomic region for amplifying the genomic region in a first PCR reaction; and at least one clamp, each configured to bind to one first allele but not any second allele at an annealing temperature in the first PCR reaction to thereby selectively suppress amplification of the one first allele but still allow amplification of other second allele(s). Kits and methods for detecting mutations in CTNNB1 and hTERT are also provided. A method for detecting or monitoring recurrence of HCC is further disclosed, which comprises determining levels of five DNA markers, including CTNNB1 mutations, hTERT mutations, TP53 mutations, RASSF1A methylation, and GSTP1 methylation.Type: GrantFiled: April 20, 2017Date of Patent: June 23, 2020Assignee: JBS Science Inc.Inventors: Wei Song, Surbhi Jain, Jamin Dean Steffen, Jeremy Wang
-
Patent number: 10422013Abstract: Hepatitis B Virus (HBV) infection results in the entry of viral genomic DNA into host liver cells. This viral relaxed circular DNA (rcDNA) is transported into the nucleus and converted into covalent closed-circular DNA (cccDNA), which serves as a template for viral transcription. Elimination of cccDNA is needed to cure HBV infection, which remains a major therapeutic challenge. A robust and sensitive method to measure cccDNA described here is useful to facilitate drug development and to monitor efficacy of therapy. A set of primers were designed in combination with sodium bisulfite treatment of viral DNA, allowing specific amplification of cccDNA without interfering amplification of rcDNA. This method can be used to further guide therapeutic development, and to provide a non-invasive alternative to monitoring of HBV-infected patients undergoing antiviral treatments.Type: GrantFiled: February 15, 2017Date of Patent: September 24, 2019Assignee: JBS Science Inc.Inventors: Surbhi Jain, Jamin Dean Steffen, Wei Song
-
Publication number: 20190225958Abstract: Disclosed is a method for the enrichment and purification of circulating, cell-free DNA (cfDNA) from a biological specimen. The method uses optimized mixtures and ratios of magnetic particles and reagents to efficiently enrich, purify, and isolate cfDNA that can be useful for cancer detection and monitoring for precision medicine. The method can be used for optimized detection of infectious diseases. The versatility of the method enables both manual use and high-throughput automation use. A kit for the use of this method is also disclosed.Type: ApplicationFiled: January 22, 2019Publication date: July 25, 2019Applicant: JBS Science Inc.Inventors: Jamin D. Steffen, Surbhi Jain, Wei Song
-
Publication number: 20170369947Abstract: Provided herein are a kit and method for detecting mutations in CTNNB1 and hTERT, and their use in detection and management of hepatocellular carcinoma (HCC). The kit comprises a first pair of primers, configured to specifically bind sequences flanking the genomic region for amplifying the genomic region in a first PCR reaction; and at least one clamp, each configured to bind to one first allele but not any second allele at an annealing temperature in the first PCR reaction to thereby selectively suppress amplification of the one first allele but still allow amplification of other second allele(s). Kits and methods for detecting mutations in CTNNB1 and hTERT are also provided. A method for detecting or monitoring recurrence of HCC is further disclosed, which comprises determining levels of five DNA markers, including CTNNB1 mutations, hTERT mutations, TP53 mutations, RASSF1A methylation, and GSTP1 methylation.Type: ApplicationFiled: April 20, 2017Publication date: December 28, 2017Applicant: JBS Science Inc.Inventors: Wei Song, Surbhi Jain, Jamin Dean Steffen, Jeremy Wang
-
Publication number: 20170233832Abstract: Hepatitis B Virus (HBV) infection results in the entry of viral genomic DNA into host liver cells. This viral relaxed circular DNA (rcDNA) is transported into the nucleus and converted into covalent closed-circular DNA (cccDNA), which serves as a template for viral transcription. Elimination of cccDNA is needed to cure HBV infection, which remains a major therapeutic challenge. A robust and sensitive method to measure cccDNA described here is useful to facilitate drug development and to monitor efficacy of therapy. A set of primers were designed in combination with sodium bisulfite treatment of viral DNA, allowing specific amplification of cccDNA without interfering amplification of rcDNA. This method can be used to further guide therapeutic development, and to provide a non-invasive alternative to monitoring of HBV-infected patients undergoing antiviral treatments.Type: ApplicationFiled: February 15, 2017Publication date: August 17, 2017Applicant: JBS Science Inc.Inventors: Surbhi Jain, Jamin Dean Steffen, Wei Song
-
Patent number: 9598735Abstract: Provided herein is a method for detecting the presence or absence of a cancer in a biological sample of an individual, by determining the level of mutation and methylation of one or more genes from a group of genes comprising TP53, CTNNB1, hTERT, RASSF1A, GSTP1, p16, p15 and SFRP-1. Also provided herein is an assay to detect p53 mutations suitable for DNA isolated from biological body fluid in order to screen cancer patients. Also provided is a method for detecting the presence or absence of a liver cancer in an individual by determining the level of methylation. Also provided is a suitable method for detecting the presence or absence of a liver cancer in an individual by determining the level of methylation of the promoter of the GSTP1 gene in body fluid such as urine or blood. Also provided is a suitable method for detecting the presence or absence of a liver cancer in an individual by determining the level of methylation of the promoter of the RASSF1A gene in body fluid such as urine or blood.Type: GrantFiled: November 14, 2013Date of Patent: March 21, 2017Assignee: JBS Science Inc.Inventors: Wei Song, Batbold Boldbaatar, Lijia Xie, Sitong Chen
-
Publication number: 20140155279Abstract: Provided herein is a method for detecting the presence or absence of a cancer in a biological sample of an individual, by determining the level of mutation and methylation of one or more genes from a group of genes comprising TP53, CTNNB1, hTERT, RASSF1A, GSTP1, p16, p15 and SFRP-1. Also provided herein is an assay to detect p53 mutations suitable for DNA isolated from biological body fluid in order to screen cancer patients. Also provided is a method for detecting the presence or absence of a liver cancer in an individual by determining the level of methylation. Also provided is a suitable method for detecting the presence or absence of a liver cancer in an individual by determining the level of methylation of the promoter of the GSTP1 gene in body fluid such as urine or blood. Also provided is a suitable method for detecting the presence or absence of a liver cancer in an individual by determining the level of methylation of the promoter of the RASSF1A gene in body fluid such as urine or blood.Type: ApplicationFiled: November 14, 2013Publication date: June 5, 2014Applicant: JBS Science Inc.Inventors: Wei SONG, Batbold BOLDBAATAR, Lijia XIE, Sitong CHEN